Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Novavax Inc (NVAX) Price & Performance

Ishares Msci Brazil ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Novavax Inc — how do they compare? Ishares Msci Brazil ETF trades at $33.98, while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Ishares Msci Brazil ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

EWZNVAX
Sector
Broad Market / FactorHealth
52-Week High
$41.75$11.19
52-Week Low
$27.36$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ, the iShares MSCI Brazil ETF, trades at $33.94, down 3.55% today, with a bearish technical signal driven by moving averages. The ETF faces headwinds from US tariffs on Brazilian goods and mixed sentiment, though oscillators suggest potential near-term support. A dividend of $0.33 is scheduled for June 2026, while institutional investors like Empowered Funds LLC have recently increased positions, indicating some confidence in Brazilian equity value.

The outlook for EWZ hinges on Brazil's economic policies and commodity markets, offering exposure to emerging market growth but with volatility risks from trade tensions and currency fluctuations. Investors should weigh the ETF's high expense ratio against alternatives like FLBR, which offers lower costs and higher dividends, as noted in recent analyst comparisons.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX